SEAMLESS Study: Innovative Digital Treatment Aims to Improve Quality of Life for Cancer Survivors

June 14, 2023 (Toronto, ON) – The SEAMLESS Study, a ground-breaking clinical trial for cancer survivors, is set to investigate the effectiveness of Mobio Interactive’s mobile programme, Mindfulness-Based Cancer Survivorship (MBCS), in reducing post-treatment side-effects for cancer survivors across Canada.

The study, led by Professor Linda E. Carlson and her team at the University of Calgary, along with the Canadian Cancer Trial Group network of cancer centre sites across Canada, aims to enhance the psychosocial care available to survivors through the use of a low-cost, evidence-based intervention delivered remotely via the digital theragnostic platform, AmDTx.

”We know that mindfulness programmes offered in-person are effective for helping people reduce anxiety, worry and depression, and manage symptoms like sleep problems, fatigue and pain, but mindfulness apps have never been rigorously tested to see if they could do the same” said Dr. Linda E. Carlson, Professor, Department of Oncology, Cumming School of Medicine, University of Calgary.

"This pivotal study lays the foundation to deliver clinically validated treatment to cancer patients who otherwise might never get help," said Dr. Bechara Saab, CEO & Chief Scientist of Mobio Interactive.

The research team includes clinical staff at five study sites across Canada through the Canadian Cancer Trials Group (CCTG) clinical trials network. If proven effective, the app-based intervention could revolutionise psychosocial care for cancer survivors by providing a low-cost, easily accessible tool to manage symptoms and transition to post-treatment life.

In recent years, the need for cost-effective, remote psychosocial care delivery options has become increasingly critical. With limitations on accessing healthcare and the growing number of survivors in Canada—currently over 800,000 diagnosed in the last decade—there is an urgent demand for innovative approaches to address the long-term negative symptoms and side-effects experienced by cancer survivors, including chronic stress, fatigue, anxiety, depression, and fear of cancer recurrence/progression.

The MBCS programme, originally developed by Drs. Linda E. Carlson and Michael Speca, has shown promising results in improving health outcomes when delivered in traditional in-person formats. In fact clinical practice guidelines now recommend mindfulness programmes should be available to all cancer survivors. However, barriers such as geographical constraints, economic limitations, and health concerns have limited accessibility. To overcome these challenges and reach a broader and more diverse group of survivors, the MBCS programme has been adapted for delivery through AmDTx.

The SEAMLESS Study will involve a pragmatic randomised controlled trial with 345 participants, comparing the AmDTx-MBCS programme to usual care. Objective biomarkers embedded within the AmDTx platform will continuously monitor cognitive stress levels.

About Mobio Interactive

Mobio Interactive is a digital health company that is meeting the exploding demand for efficacious mental healthcare with artificial intelligence-powered digital theragnostics. To learn more, visit mobiointeractive.com.

Contacts

For media inquiries and more information about the SEAMLESS Study, please contact:

Michelle Tjia
Chief of Staff
michelle@mobiointeractive.com